Immunicum
Immunicum: Key takeaways from the CMD and Q2 report (Redeye)
2019-08-21 12:26
Yesterday’s CMD provided a thorough walkthrough of ilixadencel, and most importantly, clarifying what top-line data that will be presented from the MERECA study. When it comes to the Q2 earnings, costs were somewhat above our expectations, but this doesn’t change our long-term view of the financing.
info@redeye.se (Redeye.se)
Redeye AB - Redeye.se